1. Home
  2. VERI vs BMEA Comparison

VERI vs BMEA Comparison

Compare VERI & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Veritone Inc.

VERI

Veritone Inc.

N/A

Current Price

$0.55

Market Cap

80.2M

Sector

Technology

ML Signal

N/A

Logo Biomea Fusion Inc.

BMEA

Biomea Fusion Inc.

N/A

Current Price

$1.42

Market Cap

92.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
VERI
BMEA
Founded
2014
2017
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
80.2M
92.1M
IPO Year
2017
2021

Fundamental Metrics

Financial Performance
Metric
VERI
BMEA
Price
$0.55
$1.42
Analyst Decision
Buy
Buy
Analyst Count
4
8
Target Price
$5.38
★ $7.00
AVG Volume (30 Days)
★ 5.5M
1.7M
Earning Date
11-05-2026
11-03-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 69.19
EPS
N/A
★ N/A
Revenue
★ $92,637,000.00
N/A
Revenue This Year
$11.35
N/A
Revenue Next Year
$32.92
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.58
$0.87
52 Week High
$9.42
$2.24

Technical Indicators

Market Signals
Indicator
VERI
BMEA
Relative Strength Index (RSI) 26.76 48.32
Support Level N/A $1.23
Resistance Level $1.56 $1.47
Average True Range (ATR) 0.11 0.11
MACD -0.07 -0.01
Stochastic Oscillator 0.73 39.29

Price Performance

Historical Comparison
VERI
BMEA

About VERI Veritone Inc.

Veritone Inc is a provider of artificial intelligence (AI) computing solutions and services. It generates revenue through the delivery of its Software Products and Services which consists of revenues generated from Commercial Enterprise and Government and Regulated Industries customers using the company's aiWARE platform and hiring solutions, any related support and maintenance services, and any related professional services associated with the deployment and/or implementation of such solutions, Managed Services which consist of revenues generated from Commercial Enterprise customers using company's content licensing services, advertising agency, influencer management and related services. It has presence in the United States, the United Kingdom, France, Australia, Israel, and India.

About BMEA Biomea Fusion Inc.

Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.

Share on Social Networks: